Why RedHill Biopharma Is Trouncing the Market Today
RedHill Biopharma (NASDAQ: RDHL) shot as much as 16% higher on Monday morning following the very encouraging news that one of its pipeline drugs showed promise in the treatment of patients infected with the SARS-CoV-2 coronavirus.
Image source: Getty Images.
That drug, opaganib, was administered in a 14-day compassionate-use program in Israel to a group of six hospitalized patients suffering from moderate to severe acute respiratory symptoms arising from the coronavirus.
Source Fool.com
